Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing.
J Clin Sleep Med
; 20(5): 753-763, 2024 May 01.
Article
en En
| MEDLINE
| ID: mdl-38174873
ABSTRACT
STUDY OBJECTIVES:
Low-dose cannabidiol (CBD) has become readily available in numerous countries; however, little consensus exists on its efficacy as a sleep aid. This trial explored the efficacy of 150 mg of CBD (n = 15) compared with placebo (n = 15) as a sleep aid in primary insomnia. CBD supplementation was hypothesized to decrease insomnia symptoms and improve aspects of psychological health, relative to placebo.METHODS:
Using a randomized, placebo-controlled, parallel design featuring a single-blind placebo run-in week followed by a 2-week double-blind randomized dosing phase, participants consumed the assigned treatment sublingually 60 minutes before bed nightly. Wrist-actigraphy and sleep diaries measured daily sleep. Sleep quality, sleep effort, and well-being were measured weekly over 4 in-laboratory visits. Insomnia severity and trait anxiety were measured at screening and study conclusion.RESULTS:
Insomnia severity, self-reported sleep-onset latency, sleep efficiency, and wake after sleep onset did not differ between treatments throughout the trial (all P > .05). Compared with placebo, the CBD group reported greater well-being scores throughout the trial (trial end mean difference = 2.60; standard error 1.20), transient elevated behavior following wakefulness scores after 1 week of treatment (mean difference = 3.93; standard error 1.53), and had superior objective sleep efficiency after 2 weeks of treatment (mean difference = 6.85; standard error 2.95) (all P < .05). No other significant treatment effects were observed.CONCLUSIONS:
Nightly supplementation of 150 mg CBD was similar to placebo regarding most sleep outcomes while sustaining greater well-being, suggesting more prominent psychological effects. Additional controlled trials examining varying treatment periods and doses are crucial. CLINICAL TRIAL REGISTRATION Registry Australian New Zealand Clinical Trials Registry; Name Cannabidiol (CBD) treatment for insomnia; URL https//anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620000070932; Identifier ACTRN12620000070932. CITATION Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC. Cannabidiol for moderate-severe insomnia a randomized controlled pilot trial of 150 mg of nightly dosing. J Clin Sleep Med. 2024;20(5)753-763.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Cannabidiol
/
Trastornos del Inicio y del Mantenimiento del Sueño
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Clin Sleep Med
Año:
2024
Tipo del documento:
Article
País de afiliación:
Australia
Pais de publicación:
Estados Unidos